This data is for laboratory research purposes only. Not for human or animal consumption.
What is Dihexa?
Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an angiotensin IV analog peptide investigated for neuroprotective and procognitive properties in neurodegenerative disease models. This study evaluated its efficacy against 3-nitropropionic acid (3-NP)-induced Huntington's disease-like pathology in rats.
Mechanism of Action
Dihexa functions as an angiotensin IV analog that modulates angiotensin signaling pathways implicated in neuroprotection. The compound has demonstrated procognitive and neuroprotective effects in preclinical models of Alzheimer's disease and Parkinson's disease through proposed enhancement of neurotrophic signaling and mitochondrial metabolic support. The mechanism theoretically extends to protecting against 3-NP-induced mitochondrial dysfunction, which models the energy metabolism deficits characteristic of Huntington's disease pathology.
Observed Laboratory Results
- Motor dysfunction: 3-NP exposure induced marked motor impairment over 5 weeks; Dihexa co-administration failed to attenuate motor deficits compared to 3-NP-only controls.
- Cognitive impairment: 3-NP significantly impaired spatial learning and memory consolidation; Dihexa provided no protective effect on cognitive outcomes in the 3-NP + PNB-0408 group.
- Metabolic effects: 3-NP reduced body weight gain in rats; Dihexa did not reverse weight loss or ameliorate systemic metabolic compromise.
Clinical Significance
These findings suggest Dihexa inefficacy in the 3-NP HD model, despite demonstrated neuroprotective properties in other neurodegenerative disease models. The null result highlights the necessity for mechanistic investigation in alternative Huntington's disease preclinical models or evaluation of synergistic therapeutic approaches.